A Universal Therapeutic Vaccine Leveraging Autologous Pre-Existing Immunity to Eliminate in Situ Uniformly Engineered Heterogeneous Tumor Cells

A Universal Therapeutic Vaccine Leveraging Autologous Pre-Existing Immunity to Eliminate in Situ Uniformly Engineered Heterogeneous Tumor Cells

© 2025 Wiley‐VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 37(2025), 9 vom: 21. März, Seite e2412430
1. Verfasser: Wu, Fuhua (VerfasserIn)
Weitere Verfasser: Guo, Zhaofei, Yang, Jialiang, Ou, Yangsen, Xie, Xiejin, Liao, Hu, Guo, Chenqi, Zhan, Yuxi, Wu, Haiping, Hu, Rui, Xu, Yanhua, Tang, Xue, Wang, Haolin, Ye, Lin, He, Penghui, He, Chunting, Huang, Lu, Luo, Shuang, Sun, Xun, Yang, Zhenglin
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2025
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article adeno‐associated virus (AAV) pre‐existing immunity thermoresponsive injectable hydrogel tumor cells engineering universal tumor vaccine Cancer Vaccines Spike Glycoprotein, Coronavirus spike protein, SARS-CoV-2
LEADER 01000caa a22002652c 4500
001 NLM383203821
003 DE-627
005 20250509180818.0
007 cr uuu---uuuuu
008 250507s2025 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.202412430  |2 doi 
028 5 2 |a pubmed25n1394.xml 
035 |a (DE-627)NLM383203821 
035 |a (NLM)39838750 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Wu, Fuhua  |e verfasserin  |4 aut 
245 1 2 |a A Universal Therapeutic Vaccine Leveraging Autologous Pre-Existing Immunity to Eliminate in Situ Uniformly Engineered Heterogeneous Tumor Cells 
264 1 |c 2025 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 02.05.2025 
500 |a Date Revised 02.05.2025 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2025 Wiley‐VCH GmbH. 
520 |a Tumor vaccines that activate the autologous immune system to eliminate tumor cells represent a promising approach in cancer immunotherapy. However, challenges such as tumor heterogeneity, limited antigen selection, insufficient antigen presentation, and the slow onset of de novo immune responses have resulted in poor universality and suboptimal response rates. In contrast, pathogen-specific pre-existing immunity acquired through infection or vaccination, can rapidly generate a more potent and enduring immune response upon re-encounter with the same antigen. Here, an adeno-associated virus (AAV)-based therapeutic vaccine capable of genetically modifying diverse tumor cells to uniformly overexpress and efficiently present the highly immunogenic transmembrane SARS-CoV-2 receptor binding domain (RBD), and to release RBD-enveloped virus-like particles, which awaken and enhance the RBD-specific pre-existing immunity, leading to significant tumor remission, is engineered. Mechanistically, this therapeutic vaccine leverages the robust RBD-specific pre-existing immunity and heightened antibody-mediated phagocytosis to eliminate engineered tumor cells while inducing antigen spreading, thereby provoking a more diverse tumor-specific cellular immune responses. Notably, widespread administration of vaccines against various pathogens has provided a versatile pool of pre-existing immunity that can be redirected to eradicate tumors. These findings offer a novel perspective on overcoming the limitations posed by tumor heterogeneity and personalized medicine 
650 4 |a Journal Article 
650 4 |a adeno‐associated virus (AAV) 
650 4 |a pre‐existing immunity 
650 4 |a thermoresponsive injectable hydrogel 
650 4 |a tumor cells engineering 
650 4 |a universal tumor vaccine 
650 7 |a Cancer Vaccines  |2 NLM 
650 7 |a Spike Glycoprotein, Coronavirus  |2 NLM 
650 7 |a spike protein, SARS-CoV-2  |2 NLM 
700 1 |a Guo, Zhaofei  |e verfasserin  |4 aut 
700 1 |a Yang, Jialiang  |e verfasserin  |4 aut 
700 1 |a Ou, Yangsen  |e verfasserin  |4 aut 
700 1 |a Xie, Xiejin  |e verfasserin  |4 aut 
700 1 |a Liao, Hu  |e verfasserin  |4 aut 
700 1 |a Guo, Chenqi  |e verfasserin  |4 aut 
700 1 |a Zhan, Yuxi  |e verfasserin  |4 aut 
700 1 |a Wu, Haiping  |e verfasserin  |4 aut 
700 1 |a Hu, Rui  |e verfasserin  |4 aut 
700 1 |a Xu, Yanhua  |e verfasserin  |4 aut 
700 1 |a Tang, Xue  |e verfasserin  |4 aut 
700 1 |a Wang, Haolin  |e verfasserin  |4 aut 
700 1 |a Ye, Lin  |e verfasserin  |4 aut 
700 1 |a He, Penghui  |e verfasserin  |4 aut 
700 1 |a He, Chunting  |e verfasserin  |4 aut 
700 1 |a Huang, Lu  |e verfasserin  |4 aut 
700 1 |a Luo, Shuang  |e verfasserin  |4 aut 
700 1 |a Sun, Xun  |e verfasserin  |4 aut 
700 1 |a Yang, Zhenglin  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 37(2025), 9 vom: 21. März, Seite e2412430  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnas 
773 1 8 |g volume:37  |g year:2025  |g number:9  |g day:21  |g month:03  |g pages:e2412430 
856 4 0 |u http://dx.doi.org/10.1002/adma.202412430  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 37  |j 2025  |e 9  |b 21  |c 03  |h e2412430